Compare · BIO vs NAUT
BIO vs NAUT
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Nautilus Biotechnology Inc. (NAUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and NAUT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $8.15B, about 36.8x NAUT ($221.1M).
- Over the past year, BIO is up 24.5% and NAUT is up 137.8% - NAUT leads by 113.3 points.
- NAUT has hit the wire 2 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 7 for NAUT).
- Company
- Bio-Rad Laboratories Inc.
- Nautilus Biotechnology Inc.
- Price
- -
- -
- Market cap
- $8.15B
- $221.1M
- 1M return
- +4.80%
- -19.68%
- 1Y return
- +24.46%
- +137.80%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2020
- News (4w)
- 0
- 2
- Recent ratings
- 12
- 7
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest NAUT
- Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 4 filed by Director Posard Matthew L.
- SEC Form 4 filed by Director Akinsanya Karen
- SEC Form 4 filed by Director Nazem Farzad
- SEC Form 4 filed by Director Mcilwain Matthew S
- SEC Form 4 filed by Director Epperly Melissa B,
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Large owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)